
---
title: '治疗缺血再灌注损伤新希望：犬尿酸'
categories: 
 - 新媒体
 - 科学网
 - 博客
headimg: 'https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202208/06/102529hkx9jh17qi7u0k71.jpeg'
author: 科学网
comments: false
date: Sat, 06 Aug 2022 10:24:00 GMT
thumbnail: 'https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202208/06/102529hkx9jh17qi7u0k71.jpeg'
---

<div>   
<p style="margin-left:0;text-indent:32px;text-autospace:ideograph-numeric;line-height:200%"><span style="font-size: 18px;"><span style="font-family: 宋体; line-height: 200%;"></span></span></p><p style="margin-left:0;text-indent:32px;text-autospace:ideograph-numeric;line-height:200%"><span style="font-size: 18px;"><strong><span style="font-family: 宋体; line-height: 200%;">点评：预适应、后适应和远适应现象已经是组织缺血再灌注损伤研究领域的经典范式，甚至成为药物效应参照的金标准，但关于预适应和远适应的细胞分子基础，一直都没有完全弄清楚。过去比较重视的是氧化应激、炎症和能量代谢等角度考虑，提出活性氧、激素、炎症因子和腺苷等作为效应启动因子。其中对腺苷全面研究最终使之成为临床疾病治疗药物。今天这一研究发现犬尿酸也可能是损伤适应的中介因子，而这种分子发挥作用的模式非常不同于过去许多启动因子的特点，是从能量代谢调控和线粒体功能角度，给这一分子和类似物的应用前景提供了广阔联想空间。</span></strong></span></p><p style="margin-left:0;text-indent:32px;text-autospace:ideograph-numeric;line-height:200%"><span style="font-size: 18px;"><span style="font-family: 宋体; line-height: 200%;">缺血性疾病，如心肌梗死和中风，是世界范围内的主要死亡原因。</span><strong><span style="font-family: 宋体; line-height: 200%; color: #0000FF;">到目前为止，旨在防止缺血性损伤或恢复功能组织的治疗还没有成功。犬尿喹啉酸<span style="font-family: Calibri;">KynA</span></span></strong><span style="font-family: 宋体; line-height: 200%;">是色氨酸代谢的代谢物，在心脏、大脑、肾脏和视网膜</span><strong><span style="font-family: 宋体; line-height: 200%; color: #0000FF;">缺血模型</span></strong><span style="font-family: 宋体; line-height: 200%;">中具有组织保护作用，但其保护机制尚不清楚。在<span style="font-family: Calibri;">2022</span>年<span style="font-family: Calibri;">8</span>月的《科学》杂志上，<span style="font-family: Calibri;">Wyant</span>等人报道，<span style="font-family: Calibri;">KynA</span>结合<span style="font-family: Calibri;">G</span>蛋白偶联受体<span style="font-family: Calibri;">35 (GPR35)</span>激活下游信号转导，一旦内化，通过促进<span style="font-family: Calibri;">ATP</span>合酶二聚和失活，间接与三磷酸腺苷合酶抑制因子<span style="font-family: Calibri;">1 (IF1)</span>相互作用，在缺血时阻断<span style="font-family: Calibri;">ATP</span>耗尽。这一心脏保护机制可为预防或治疗缺血性损伤提供进一步的探索方向。</span><br></span></p><p style="margin-left:0;text-indent:32px;text-autospace:ideograph-numeric;line-height:200%"><span style="font-size: 18px;"><span style="font-family: 宋体; line-height: 200%;"><a href="https://www.science.org/doi/10.1126/science.add4629" target="_blank">Mitochondria rescue cells from ischemic injury | Science</a></span></span></p><p style="margin-left:0;text-indent:32px;text-autospace:ideograph-numeric;line-height:200%"><span style="font-family: 宋体; line-height: 200%; font-size: 18px;">在人心力衰竭的心肌中<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">GPR35</span>表达上调，在缺氧诱导因子<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">1 (HIF-1)</span>的控制下，其表达在缺氧时增加，<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">HIF-1</span>指导多种转录程序以应对氧供应降低。关于<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">GPR35</span>在缺血过程中组织保护作用的研究得出了相互矛盾的结果。<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">Wyant</span>等人使用多种方法提供了令人信服的证据，<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">KynA</span>通过激活<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">GPR35</span>对缺血再灌注<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">(IR)</span>损伤具有心脏保护作用。他们表明，在缺乏<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">GPR35</span>的小鼠和表达该受体突变型的人诱导的多能干细胞来源的心肌细胞中，<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">KynA</span>不能防止<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">IR</span>损伤。<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">KynA</span>的心脏保护作用可被几种<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">GPR35</span>激动剂所模拟。 </span></p><p style="margin-left:0;text-indent:32px;text-autospace:ideograph-numeric;line-height:200%"><span style="font-family: 宋体; line-height: 200%; font-size: 16px;">低氧诱导因子<span style="font-size: 18px; font-family: Calibri;">HIF</span><span style="font-size: 18px; font-family: 宋体;">相关研究</span><span style="font-size: 18px; font-family: Calibri;">2019</span><span style="font-size: 18px; font-family: 宋体;">年曾经获得医学诺贝尔奖，这不仅是低氧感受的关键分子，也是细胞适应低氧的关键信号。</span><span style="font-size: 18px; font-family: Calibri;">HIF</span><span style="font-size: 18px; font-family: 宋体;">转录因子是异二聚体，由缺氧稳定的氧不稳定的α亚基和组成型表达的β亚基组成。</span><span style="font-size: 18px; font-family: Calibri;">HIF</span><span style="font-size: 18px; font-family: 宋体;">脯氨酸羟化酶</span><span style="font-size: 18px; font-family: Calibri;">(PHDs)</span><span style="font-size: 18px; font-family: 宋体;">是α</span><span style="font-size: 18px; font-family: Calibri;">-</span><span style="font-size: 18px; font-family: 宋体;">酮戊二酸酯</span><span style="font-size: 18px; font-family: Calibri;">(</span><span style="font-size: 18px; font-family: 宋体;">α</span><span style="font-size: 18px; font-family: Calibri;">KG)</span><span style="font-size: 18px; font-family: 宋体;">依赖的双加氧酶，其氧依赖性羟基化</span><span style="font-size: 18px; font-family: Calibri;">HIF</span><span style="font-size: 18px; font-family: 宋体;">α，促进其泛素化和蛋白酶体降解。</span><span style="font-size: 18px; font-family: Calibri;">HIF</span><span style="font-size: 18px; font-family: 宋体;">激活通过多种机制改善缺血相关结果，主要是通过重编程代谢介导的氧稳态恢复和诱导血管生成</span><span style="font-size: 18px; font-family: Calibri;">(</span><span style="font-size: 18px; font-family: 宋体;">血管形成</span><span style="font-size: 18px; font-family: Calibri;">)</span><span style="font-size: 18px; font-family: 宋体;">。在缺血预处理中</span><span style="font-size: 18px; font-family: Calibri;">HIF</span><span style="font-size: 18px; font-family: 宋体;">也</span>发挥很重要作用，这是一种短时间的非致命缺血保护机制，以防止随后延长的缺血损伤。<span style="font-size: 18px; font-family: 宋体;">抑制</span><span style="font-size: 18px; font-family: Calibri;">HIF</span><span style="font-size: 18px; font-family: 宋体;">通路会损害不同类型的缺血预处理。 </span></span></p><p style="margin-left:0;text-indent:32px;text-autospace:ideograph-numeric;line-height:200%"><span style="font-size: 18px;"><span style="font-family: 宋体; line-height: 200%; font-size: 16px;">一种临床实用的改善缺血性疾病结局的方法是</span><strong><span style="font-family: 宋体; line-height: 200%; color: #0000FF; font-size: 16px;">远端缺血预处理</span></strong><span style="font-family: 宋体; line-height: 200%; font-size: 16px;"><span style="font-size: 18px; font-family: Calibri;">(RIPC)</span><span style="font-size: 18px; font-family: 宋体;">，即对非重要器官的短暂缺血保护远端器官。多年来，人们一直在寻找</span><span style="font-size: 18px; font-family: Calibri;">RIPC</span><span style="font-size: 18px; font-family: 宋体;">的分子介质，希望它们可能有助于治疗心血管疾病。</span><span style="font-size: 18px; font-family: Calibri;">Wyant</span><span style="font-size: 18px; font-family: 宋体;">等人的研究扩展了作者之前的工作，表明</span><span style="font-size: 18px; font-family: Calibri;">KynA</span><span style="font-size: 18px; font-family: 宋体;">在</span><span style="font-size: 18px; font-family: Calibri;">RIPC</span><span style="font-size: 18px; font-family: 宋体;">小鼠模型中提供心脏保护。他们表明，抑制</span><span style="font-size: 18px; font-family: Calibri;">PHD2</span><span style="font-size: 18px; font-family: 宋体;">导致</span><span style="font-size: 18px; font-family: Calibri;">HIF</span><span style="font-size: 18px; font-family: 宋体;">激活，从而保护小鼠免受心脏</span><span style="font-size: 18px; font-family: Calibri;">IR</span><span style="font-size: 18px; font-family: 宋体;">损伤。全身</span><span style="font-size: 18px; font-family: Calibri;">PHD2</span><span style="font-size: 18px; font-family: 宋体;">缺失或骨骼肌中增加循环α</span><span style="font-size: 18px; font-family: Calibri;">KG</span><span style="font-size: 18px; font-family: 宋体;">，驱动肝脏生成和分泌</span><span style="font-size: 18px; font-family: Calibri;">KynA</span><span style="font-size: 18px; font-family: 宋体;">，这是介导心脏缺血保护的必要和充分的。</span></span></span></p><p style="margin-left:0;text-indent:32px;text-autospace:ideograph-numeric;line-height:200%"><span style="font-family: 宋体; line-height: 200%; font-size: 18px;">心肌细胞中<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">95%</span>以上的<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">ATP</span>是由线粒体内膜<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">ATP</span>合酶在氧化磷酸化过程中产生的。在正常呼吸的线粒体中，<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">ATP</span>合酶利用沿呼吸链的电子传递产生的质子动力<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">(PMF)</span>，从二磷酸腺苷<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">(ADP)</span>和磷酸腺苷产生<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">ATP</span>。缺血时，<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">PMF</span>耗散，<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">ATP</span>合酶逆转方向水解<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">ATP</span>，导致细胞死亡。这种水解活性受到<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">IF1</span>的限制，从而保存细胞能量。<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">Wyant</span>等人提出，一旦被激活，<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">GPR35</span>会转到线粒体外膜，在那里它会间接地与<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">IF1</span>相互作用。内化的<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">GPR35</span>抑制线粒体腺苷酸环化酶<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">[</span>以及环磷酸腺苷<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">(cAMP)</span>的产生<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">]</span>，进而抑制蛋白激酶<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">A (PKA)</span>，这有利于去磷酸化的<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">IF1</span>，抑制剂的活性形式。他们表明，<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">IF1</span>促进<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">ATP</span>合酶二聚并防止缺血时<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">ATP</span>丢失<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">(</span>见图<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">)</span>。 </span></p><p style="margin-left:0;text-indent:32px;text-autospace:ideograph-numeric;line-height:200%"><span style="font-family: 宋体; line-height: 200%; font-size: 18px;"><img src="https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202208/06/102529hkx9jh17qi7u0k71.jpeg" title alt="111.jpeg" referrerpolicy="no-referrer"><br></span></p><p style="margin-left:0;text-indent:32px;text-autospace:ideograph-numeric;line-height:200%"><span style="font-family: 宋体; line-height: 200%; font-size: 16px;"><span style="font-size: 18px; font-family: Calibri;">IF1</span><span style="font-size: 18px; font-family: 宋体;">与</span><span style="font-size: 18px; font-family: Calibri;">ATP</span><span style="font-size: 18px; font-family: 宋体;">合酶结合还会影响线粒体通透性过渡孔</span><span style="font-size: 18px; font-family: Calibri;">(mPTP)</span><span style="font-size: 18px; font-family: 宋体;">，这是氧化应激条件下在线粒体内膜形成的一种高电导非特异性通道，导致去极化和</span><span style="font-size: 18px; font-family: Calibri;">ATP</span><span style="font-size: 18px; font-family: 宋体;">合成停止，对能量守恒产生灾难性后果。</span><span style="font-size: 18px; font-family: Calibri;">mPTP</span><span style="font-size: 18px; font-family: 宋体;">含有</span><span style="font-size: 18px; font-family: Calibri;">ATP</span><span style="font-size: 18px; font-family: 宋体;">合酶二聚体，</span><span style="font-size: 18px; font-family: Calibri;">IF1</span><span style="font-size: 18px; font-family: 宋体;">结合可能会阻止</span><span style="font-size: 18px; font-family: Calibri;">mPTP</span><span style="font-size: 18px; font-family: 宋体;">在缺血的低</span><span style="font-size: 18px; font-family: Calibri;">pH</span><span style="font-size: 18px; font-family: 宋体;">条件下开放。事实上，低</span><span style="font-size: 18px; font-family: Calibri;">pH</span><span style="font-size: 18px; font-family: 宋体;">有利于</span><span style="font-size: 18px; font-family: Calibri;">IF1</span><span style="font-size: 18px; font-family: 宋体;">与酶结合。此外，在肥厚的心脏中</span><span style="font-size: 18px; font-family: Calibri;">IF1</span><span style="font-size: 18px; font-family: 宋体;">上调，促进无活性</span><span style="font-size: 18px; font-family: Calibri;">ATP</span><span style="font-size: 18px; font-family: 宋体;">合酶四聚体的形成，从而触发线粒体活性氧</span><span style="font-size: 18px; font-family: Calibri;">(ROS)</span><span style="font-size: 18px; font-family: 宋体;">的产生，稳定</span><span style="font-size: 18px; font-family: Calibri;">HIF-1a</span><span style="font-size: 18px; font-family: 宋体;">并激活刺激糖酵解的代谢开关</span><span style="font-size: 18px; font-family: Calibri;">(14)</span><span style="font-size: 18px; font-family: 宋体;">。有可能在缺血时</span><span style="font-size: 18px; font-family: Calibri;">IF1</span><span style="font-size: 18px; font-family: 宋体;">对</span><span style="font-size: 18px; font-family: Calibri;">ATP</span><span style="font-size: 18px; font-family: 宋体;">合酶的抑制也启动了</span><span style="font-size: 18px; font-family: Calibri;">ROS</span><span style="font-size: 18px; font-family: 宋体;">信号传导，从而影响心肌细胞代谢。 </span></span></p><p style="margin-left:0;text-indent:32px;text-autospace:ideograph-numeric;line-height:200%"><span style="font-family: 宋体; line-height: 200%; font-size: 18px;">缺血时，缺氧诱导因子<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">(HIF)</span>诱导<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">G</span>蛋白偶联受体<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">35 (GPR35)</span>表达，然后与<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">KynA</span>结合。<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">GPR35</span>内化到线粒体外膜，抑制线粒体腺苷酸环化酶<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">(sAC)</span>，从而阻止蛋白激酶<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">A (PKA)</span>对<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">ATP</span>合酶抑制因子<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">1 (IF1)</span>的磷酸化<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">(P)</span>。<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">IF1</span>去磷酸化导致<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">ATP</span>合酶二聚，阻止<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">ATP</span>水解，促进能量守恒。 </span></p><p style="margin-left: 0px; text-indent: 32px; line-height: 200%;"><span style="font-family: 宋体; line-height: 200%; font-size: 18px;"><span style="line-height: 200%; font-size: 18px; font-family: Calibri;">Wyant</span>等人的研究支持了<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">KynA</span>和更广泛的<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">GPR35</span>激动剂的进一步研究，包括比<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">KynA</span>效力更强的合成化合物，用于预防或治疗缺血性损伤。他们的发现也为<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">kynurenine</span>单加氧酶抑制剂的组织保护作用提供了分子解释，该抑制剂促进<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">KynA</span>的积累，从而具有心脏保护潜力。同样，<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">IF1</span>模拟物的临床前研究在心脏缺血模型中也产生了很有前景的结果。<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">KynA</span>激活<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">GPR35</span>刺激脂质代谢和产热及抗炎基因表达，增加脂肪组织的能量消耗。因此，<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">KynA</span>能否诱导一个影响心肌细胞代谢的转录程序<span style="line-height: 200%; font-size: 18px; font-family: Calibri;">?</span>阐明协调缺血保护的途径和调节它们的治疗方法的发展对预后不良的患者群体具有重要的临床意义。</span></p>                    <br><br>
                                        <label style="font-size:13px; color:#850f0f">转载本文请联系原作者获取授权，同时请注明本文来自孙学军科学网博客。<br>链接地址：</label><a href="https://blog.sciencenet.cn/blog-41174-1350168.html" target="_blank" style="font-size:13px; color:#850f0f">https://blog.sciencenet.cn/blog-41174-1350168.html </a>
  <br><br>上一篇：<a href="http://blog.sciencenet.cn/blog-41174-1349985.html" target="_black">维生素K是铁死亡的内源性抑制剂</a><br>下一篇：<a href="http://blog.sciencenet.cn/blog-41174-1350353.html" target="_black">如何查找管理和阅读文献？</a>                    <!--大赛结束-->
                                        
  
</div>
            